Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Receptor reserve at striatal dopamine autoreceptors: implications for selectivity of dopamine agonists.

Meller E, Helmer-Matyjek E, Bohmaker K, Adler CH, Friedhoff AJ, Goldstein M.

Eur J Pharmacol. 1986 Apr 16;123(2):311-4.

PMID:
3709668
2.

Relationship between receptor occupancy and response at striatal dopamine autoreceptors.

Meller E, Bohmaker K, Namba Y, Friedhoff AJ, Goldstein M.

Mol Pharmacol. 1987 Jun;31(6):592-8.

PMID:
2885734
4.

Receptor reserve at striatal dopamine receptors modulating the release of [3H]dopamine.

Yokoo H, Goldstein M, Meller E.

Eur J Pharmacol. 1988 Oct 18;155(3):323-7.

PMID:
3234490
5.

Absence of receptor reserve at striatal dopamine receptors regulating cholinergic neuronal activity.

Meller E, Enz A, Goldstein M.

Eur J Pharmacol. 1988 Oct 11;155(1-2):151-4.

PMID:
2907486
7.

Evidence that striatal synthesis-inhibiting autoreceptors are dopamine D3 receptors.

Meller E, Bohmaker K, Goldstein M, Basham DA.

Eur J Pharmacol. 1993 Nov 2;249(1):R5-6.

PMID:
7904244
10.
11.

Delayed inhibition of dopamine synthesis by gamma-butyrolactone and baclofen: dopamine autoreceptor supersensitivity?

Argiolas A, Fadda F, Melis MR, Marcou M, Porceddu ML, Gessa GL.

Eur J Pharmacol. 1982 Nov 5;85(1):23-7.

PMID:
6818043
12.
18.

Pharmacological profiles of the putative dopamine autoreceptor agonists 3-PPP and TL-99.

Martin GE, Haubrich DR, Williams M.

Eur J Pharmacol. 1981 Nov 19;76(1):15-23.

PMID:
7318920
19.

D-1 type of dopamine autoreceptors are not involved in the regulation of dopamine synthesis in the striatum.

Watanabe H, Suda H, Sekihara S, Nomura Y.

Jpn J Pharmacol. 1987 Mar;43(3):327-30.

20.

Supplemental Content

Support Center